RxDoctor Payments Data

Samuel Sencil, DO

Internal Medicine · Bowman, GANPI 1699816322

Payments from drug & device makers

$1,597in general payments, 2019–2025

Across 82 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$331
  • AstraZeneca$322
  • Lilly USA, LLC$297
  • Novo Nordisk$83
  • Alkermes, Inc.$69
  • Kowa Pharmaceuticals America, Inc.$53
  • plus $441 from 16 others

What the payments were for

  • Food & beverage$1,597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,597 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$1,172
Medicare patients
43
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide225$286,409
JardianceEmpagliflozin135$150,853
BiktarvyBictegrav/Emtricit/Tenofov Ala34$146,343
OzempicSemaglutide87$138,648
FarxigaDapagliflozin Propanediol108$117,076
VraylarCariprazine Hcl57$86,686
TrulicityDulaglutide51$64,252
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$60,338
EliquisApixaban59$58,349
XareltoRivaroxaban15$20,318
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$19,165
RybelsusSemaglutide12$18,964
TrintellixVortioxetine Hydrobromide13$15,130
JanuviaSitagliptin Phosphate11$10,693
Novolog FlexpenInsulin Aspart36$7,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$297$350,661276 claims
Novo NordiskOzempic, Rybelsus$83$157,61399 claims
Boehringer IngelheimJardiance$15$150,853135 claims
AstraZenecaFarxiga, Symbicort$322$124,001127 claims
AbbVieVraylar$331$86,68657 claims
GSKTrelegy Ellipta$19$60,33862 claims
PfizerEliquis$45$58,34959 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$28$15,13013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Bowman

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →